ABBOTT 冠狀病毒響應
聯絡我們
Diagnostics
About Abbott
臺灣

Global Point of Care

HIV 診斷照護

我們的 HIV 診斷解決方案可使您作出能夠對人、政府和社會產生有力影響並且挽救生命的決定。透過提供急需的照護，易受感染族群獲得了前所未有的治療機會，而醫療保健專業人員則得到了診斷、治療和阻斷 HIV 傳播。

床邊檢測能使全世界數百萬患者獲得有效照護。

UNAIDS 呼籲在 2030 年前終結 AIDS 疫情。1 要實現這些遠大的目標，人們需要快速擴大診斷、治療和病毒抑制範圍，尤其是在易受感染族群中。憑藉業界領先的產品系列，Abbott 是唯一能與您合作，以確保順利實現每個目標的合作夥伴。

結果就是最好的證明。自 2010 年以來，檢測和治療的進一步普及已使全球 AIDS 相關死亡人數下降 26%。2

Abbott is the only company with point-of-care diagnostic solutions that addresses nearly every key population along the entire HIV cascade of care. Abbott is the only company with point-of-care diagnostic solutions that addresses nearly every key population along the entire HIV cascade of care. Abbott is the only company with point-of-care diagnostic solutions that addresses nearly every key population along the entire HIV cascade of care.

Abbott 是全球首屈一指的 HIV 快速檢測產品製造商。3

瞭解我們的 HIV POC 解決方案

這些 Abbott 產品可助您在 HIV 預防和診斷領域取得領先優勢。

我們是 HIV 快速床邊檢測領域的全球領導者。3 目前，超過 120 個國家的醫療保健專業人員正使用 Abbott HIV 檢測以及早識別感染、預防傳播及改善 AIDS 疫情。

章節導覽
HIV 預防和早期嬰兒診斷

每個嬰兒在出生時都不應該帶有 HIV。

消除新增嬰兒 HIV 感染病例是終結 HIV 疫情的重要工作之一。此項工作需要先從減少 HIV 和梅毒的母嬰傳播著手。接受梅毒/HIV 診斷和及時治療可最大程度減少胎兒面臨的感染風險。對於已感染 HIV 的嬰兒，使用精準的分子檢測及早診斷嬰兒病情可避免嬰兒死亡。為最年幼的患者尋找最佳解決方案。

HIV 篩檢

快速終結 HIV 疫情：主動篩檢病例。

實現 UNAIDS 目標的關鍵步驟是，確保能立刻準確地識別 HIV 患者。立刻識別 HIV 陽性患者不僅能促使患者迅速接受恰當照護，還可幫助預防疾病的進一步傳播。我們潛心設計出各種易用且可擴展的 POC 檢測產品，以便世界各地有需要的人士和機構（包括偏遠地區的分散機構）可以使用該等檢測產品主動篩檢病例。 

Determine HIV-1/2

Determine™ HIV-1/2

經過數十億次檢測並經實踐證明的快速 HIV 篩檢。Determine™ HIV-1/2可檢測多種HIV亞型（請參閱IFU）這種多功能性檢測可協助全球醫護人員診斷個體感染、監控 HIV 盛行率、並快速提供適當的照護。

增長見聞

Solutions-Cardio-quotation-panel-tablet-768

慢性心臟代謝疾病解決方案頁面

如果能以少得多的步驟更有效地治療更多心臟代謝疾病患者，您覺得怎樣？瞭解 Abbott POCT 產品帶來的無限可能。

參考資料

  1. Joint United Nations Programme on HIV/AIDS (UNAIDS) 2014. 90-90-90 An ambitious treatment target to help end the AIDS epidemic. Accessed: July 5, 2016. http://www.unaids.org/sites/default/files/media_asset/90-90-90_en_0.pdf
  2. Joint United Nations Programme on HIV/AIDS. UNAIDS Global AIDS Update. 2016.
  3. HIV – Global Fund HIV and Malaria Manufacturers Engagement, Sept. 2015, Slide 43 on “Trends in HIV RDT market.”
  4. Hsue P et al (Song X presenting). A longitudinal analysis of comorbidities among human immunodeficiency virus (HIV) patients and matched non-HIV controls in the USA. IDWeek, New Orleans, abstract 950, 2016.
  5. Lawn SD, Kerkhoff AD, Vogt M, Wood R. Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. Lancet Infect Dis. 2012 Mar;12(3):201-9.

A Leader In Rapid Point-of-care Diagnostics.

產品目錄
床邊檢測：面向全球醫療保健的解決方案
联络我们
产品文档搜索
产品演示
INTEREST-BASED ADS

©2024 Abbott. All rights reserved. Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

This website is governed by applicable U.S. laws and governmental regulations. The products and information contained herewith may not be accessible in all countries, and Abbott takes no responsibility for such information which may not comply with local country legal process, regulation, registration and usage.

Your use of this website and the information contained herein is subject to our Website Terms and Conditions and Privacy Policy. Photos displayed are for illustrative purposes only. Any person depicted in such photographs is a model. GDPR Statement

Not all products are available in all regions. Check with your local representative for availability in specific markets. For in vitro diagnostic use only.  For i-STAT test cartridge information and intended use, refer to individual product pages or the cartridge information (CTI/IFU) in the i-STAT Support area.